4 / 12
allied
academies
Page 28
Notes:
September 23-24, 2019 | Prague, Czech Republic
2
nd
International Conference on
Palliative Care
Clinical Trials and Pharmacovigilance
Joint Event
&
Effect of erythropoiesis-stimulating agent therapy in patients receiving palliative care
of chronic kidney disease
Ka Wai Alice Mok
1
, Kai Ming Chow
2
, Cheuk Chun Szeto
2
, Agnes Shin Man Choy
2
, Jack Kit Chung Ng
2
, Jack Kit Chung
Ng
2
, Chi Bon Leung
2
and
Philip Kam Tao Li
2
1
Shatin Hospital, Hong Kong
2
The Chinese University of Hong Kong, Hong Kong
Palliativecareprogramforpatientswithchronickidneydisease
was started a decade ago in Hong Kong, aiming to provide a
cross-specialty multidisciplinary palliative care for those who
choose not to proceed with dialysis. Anemia is a common
complication seen in patients with chronic kidney disease,
leading to significant morbidity and mortality, contributing
to the top symptom of fatigue among this group of patients.
While the benefits of erythropoiesis-stimulating agent (ESA)
have been well established for patients with chronic kidney
disease receiving dialysis, the effect of this treatment for those
who decide for non-dialysis palliative care is less well studied.
Objective:
Ourcenterconductedaretrospectiveobservational
studytoevaluatetheeffectofESAintreatinganemiaofchronic
kidney disease among adult patients receiving palliative care
whodecidednot for dialysis in terms of the transfusionburden
and hospitalization need. Thirty-nine patients receiving ESA
werematchedwithacontrolgroupof39patientswithoutESA.
Results:
Over a 1-year observation period, both the
transfusion rate and admission rate were found to be
significantly lower in the in the ESA group after adjustment
for comorbidities. The mean hemoglobin concentration
at the end of study period was significantly higher in the
ESA group than the control group. No patients in the ESA
group had to terminate the drug treatment due to adverse
effects.
Conclusion:
ESA could lessen the burden of palliative
care for patients with chronic kidney disease by reducing
transfusion requirement and hospitalization. The option of
ESA should be considered in the care plan for patients with
chronic kidney disease opted for non-dialysis palliative care.
Speaker Biography
Ka Wai Alice MOK attained her degree in medicine from the Chinese
University of Hong Kong. She completed her specialist training in Palliative
Medicine and is the fellow of the Hong Kong College of Physician. She is
currently the Associate Consultant of the Palliative Care Unit of Shatin
Hospital in Hong Kong and has actively participated in the development
of palliative care service for patients with end-stage renal failure. She is a
regular invited speaker to talk on the different topics in palliative care by
many healthcare societies. She is also the clinical tutor for undergraduate
medical students and the lecturer for post-graduate degrees in End-of-
Life Care Program of the Chinese University of Hong Kong.
e:
mkw474@gmail.comJournal of Primary Care and General Practice | Volume 2
J Prim Care Gen Pract, Volume:2